The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Investment will fund expansion to meet rising demand for CRDMO services
Subscribe To Our Newsletter & Stay Updated
